Fund shareholders of KIORA PHARMACEUTICALS INC
ISIN US49721T5074 · United States · LEI 549300395G8DB8ZFV365
- Fund shareholders
- 5
- Of which ETFs
- 0 5 other funds
- Value held
- 93.9K $
- Share of capital
- 1.1 % of 4.4M shares on Aug 5, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 20,571 | 43K $ | 0.00 % | 0.46 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 19,861 | 38.3K $ | 0.45 % | as of Mar 31, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 3,446 | 7.2K $ | 0.08 % | as of Feb 28, 2026 ↗ | |
| Omni Small-Cap Value Fund Bridgeway Funds, Inc. | 2,000 | 3.9K $ | 0.00 % | 0.05 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 747 | 1.6K $ | 0.02 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Omni Small-Cap Value Fund Bridgeway Funds, Inc. | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 5 | 0 | 46,625 | +17.3 % |
| 2026Q1 | 5 | 0 | 39,762 | -0.3 % |
| 2025Q4 | 5 | 0 | 39,901 | +74.2 % |
| 2025Q3 | 5 | 0 | 22,909 | +6.7 % |
| 2025Q2 | 5 | 0 | 21,468 | +6.1 % |
| 2025Q1 | 5 | +1 | 20,236 | +2.5 % |
| 2024Q4 | 4 | +3 | 19,751 | +623.7 % |
| 2024Q3 | 1 | 2,729 |
Institutional managers
14 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 167,941 | 324.1K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 49,533 | 95.6K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 47,850 | 92.3K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 14,719 | 28.4K $ | as of Mar 31, 2026 |
| TWO SIGMA SECURITIES, LLC | 12,019 | 23.2K $ | as of Mar 31, 2026 |
| Rangeley Capital, LLC | 10,000 | 19.3K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 1,408 | 2.7K $ | as of Mar 31, 2026 |
| UBS Group AG | 1,301 | 2.5K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 995 | 1.9K $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 256 | 494 $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 58 | 112 $ | as of Mar 31, 2026 |
| Caitong International Asset Management Co., Ltd | 6 | 12 $ | as of Mar 31, 2026 |
| Activest Wealth Management | 2 | 4 $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 2 | 3 $ | as of Mar 31, 2026 |
Declared shareholders of KIORA PHARMACEUTICALS INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Alyeska Investment Group, L.P. and 2 others | 9.99 % | 394,668 | as of Mar 31, 2026 · SCHEDULE 13G |
| Nantahala Capital Management, LLC and 2 others | 9.99 % | 438,469 | as of Mar 31, 2026 · SCHEDULE 13G |
| Perceptive Advisors LLC and 2 others | 9.99 % | 438,471 | as of Apr 6, 2026 · SCHEDULE 13G |
| NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 3.388 % | 148,736 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of KIORA PHARMACEUTICALS INC". https://titelia.com/en/stocks/kiora-pharmaceuticals-inc-US49721T5074